Literature DB >> 7525629

Presence of immunoreactive corticotropin-releasing hormone in normal and polycystic human ovaries.

G Mastorakos1, C D Scopa, A Vryonidou, T C Friedman, D Kattis, C Phenekos, M J Merino, G P Chrousos.   

Abstract

Recently, we demonstrated the presence of immunoreactive (Ir) CRH and its receptors in the rat ovary. To determine whether CRH is also present in human ovaries, we examined ovaries from normal women and patients with the polycystic ovarian syndrome (PCOS). Immunoreactive CRH in normal human ovaries had a similar distribution to that of rat ovarian IrCRH, as determined by immunohistochemistry. Thus, immunoreactivity was intense in the cytoplasm of thecal cells surrounding the ovarian follicles, in luteinized cells of the stroma, and in a subpopulation of cells within the corpora lutea. No IrCRH was present in oocytes of primordial follicles. Polycystic ovaries also had IrCRH in thecal cells; however, CRH immunostaining was less prominent or completely absent from the stroma or the sparsely present corpora lutea and was clearly detected in oocytes of primordial follicles. Using a specific RIA, the IrCRH content in extracts of normal ovaries was higher than that in polycystic ovaries (mean +/- SD, 0.075 +/- 0.02 vs. 0.038 +/- 0.009 pmol/g wet tissue, respectively; P < 0.05). Human follicular fluid samples collected from women undergoing ovarian hyperstimulation for assisted reproduction had low, but detectable, levels of IrCRH (mean +/- SD, 4.975 +/- 1.179 pmol/L), whereas IrCRH was undetectable in concurrently drawn plasma samples. IrCRH detected in normal and polycystic ovaries and in follicular fluid had similar chromatographic mobility to that of rat/human CRH-(1-41) by reverse phase HPLC. We conclude that IrCRH is present in normal human ovaries and follicular fluid, suggesting that this neuropeptide may play a regulatory role in one or more of the various functions of this gonad, such as ovulation and/or luteolysis, through its proinflammatory properties and/or its auto/paracrine regulation of steroid biosynthesis, in analogy to its action on testosterone secretion by the Leydig cell. Its decreased concentration and localization in primary oocytes of polycystic ovaries may be related to the increased androgen biosynthesis by the theca and stroma and/or to the oocyte dysfunction observed in women with the polycystic ovarian syndrome, respectively.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525629     DOI: 10.1210/jcem.79.4.7525629

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Corticotropin-releasing factor (CRF) and stress-related reproductive failure: the brain as a state of the art or the ovary as a novel clue?

Authors:  R E Nappi; S Rivest
Journal:  J Endocrinol Invest       Date:  1995-12       Impact factor: 4.256

Review 2.  Human endometrium as a neuroendocrine tissue: expression, regulation and biological roles of endometrial corticotropin-releasing hormone (CRH) and opioid peptides.

Authors:  E Zoumakis; A N Margioris; A Makrigiannakis; C Stournaras; A Gravanis
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

Review 3.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

4.  Role of corticotropin-releasing hormone in ovarian steroidogenesis.

Authors:  Mariko Murase; Tsuguo Uemura; Yoshihito Kondoh; Toshiya Funabashi; Fumiki Hirahara
Journal:  Endocrine       Date:  2002-08       Impact factor: 3.633

5.  Local production of corticotropin releasing hormone is increased in experimental intestinal inflammation in rats.

Authors:  E A van Tol; P Petrusz; P K Lund; M Yamauchi; R B Sartor
Journal:  Gut       Date:  1996-09       Impact factor: 23.059

Review 6.  The emerging role of peripheral corticotropin-releasing hormone (CRH).

Authors:  I Ilias; G Mastorakos
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

Review 7.  Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset.

Authors:  L Ibáñez; F de Zegher; N Potau
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

8.  Peritoneal fluid levels of immunoreactive corticotropin-releasing factor (CRF) and CRF-binding protein (CRF-BP) in healthy and endometriosic women.

Authors:  P Florio; M Busacca; M Vignali; P Viganò; R J Woods; P J Lowry; A R Genazzani; S Luisi; M Santuz; F Petraglia
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

9.  Corticotropin-releasing hormone stimulates expression of leptin, 11beta-HSD2 and syncytin-1 in primary human trophoblasts.

Authors:  Fabian B Fahlbusch; Matthias Ruebner; Gudrun Volkert; Ramona Offergeld; Andrea Hartner; Carlos Menendez-Castro; Reiner Strick; Manfred Rauh; Wolfgang Rascher; Jörg Dötsch
Journal:  Reprod Biol Endocrinol       Date:  2012-09-12       Impact factor: 5.211

Review 10.  Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence.

Authors:  Jie Qiao; Huai L Feng
Journal:  Hum Reprod Update       Date:  2010-07-16       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.